Fulminant 2-chlorodeoxyadenosine-related peripheral neuropathy in a patient with paraneoplastic neurological syndrome associated with lymphoma.
2-chlorodeoxyadenosine (2-CdA) has been demonstrated to be a neurotoxic agent when used at significantly greater doses than currently recommended for clinical use. In this report we describe a case of a 37-years-old man lymphoplasmacytoid malignant lymphoma and pre-existing paraneoplastic neurological syndrome who died of an apparent rapidly progressive sensorimotor peripheral neuropathy after completing treatment with two courses of low-doses of 2-CdA.
Warzocha
K
K
2nd Department of Internal Medicine, Medical University of Lódź, Copernicus Hospital, Poland.
Krykowksi
E
E
Góra-Tybor
J
J
Fronczak
A
A
Robak
T
T
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017338:Cladribine / Q000009:adverse effects*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy; D008297:Male; D010257:Paraneoplastic Syndromes / Q000150:complications*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000209:etiology
D000970:Antineoplastic Agents; D017338:Cladribine